

| Particulars | Q4'FY17 | Q3'FY18 | Q4'FY18 | YoY Growth | QoQ Growth |
|---|----------|---------|---------|------------|------------|
| | (Rs Crs) | | | (%) | |
| Total Revenue from Operations (Net of Excise) | 1,598 | 2,068 | 2,252 | 41% | 9% |
| Pharmaceuticals | 804 | 1,101 | 1,238 | 54% | 12% |
| Life Science Ingredients | 743 | 922 | 968 | 30% | 5% |
| Drug Discovery Solutions | 51 | 45 | 47 | -8% | 5% |
| Total Expenditure | 1,293 | 1,651 | 1,794 | 39% | 9% |
| Other Income | 11 | 3 | 23 | 118% | 611% |
| EBITDA from Operations | | | | | |
| Pharmaceuticals | 216 | 245 | 298 | 38% | 22% |
| Life Science Ingredients | 116 | 206 | 187 | 62% | -9% |
| Drug Discovery Solutions | 6 | 3 | 10 | 85% | 230% |
| Corporate (Expenses)/Income | (22) | (23) | (15) | | |
| Total | 316 | 431 | 481 | 52% | 12% |
| One time expenses | 0 | (10) | 0 | | |
| Reported EBITDA | 316 | 420 | 481 | 52% | 14% |
| Depreciation and Amortization | 75 | 82 | 182 | | |
| Normal | 75 | 82 | 91 | 21% | 11% |
| One-time | 0 | 0 | 91 | | |
| Finance Cost | 80 | 77 | 72 | -10% | -6% |
| Profit before Tax | 160 | 261 | 227 | 42% | -13% |
| Tax Expenses (Net) | 11 | 48 | 74 | 570% | 53% |
| Minority Interest | (1) | 0 | (2) | | |
| Net Profit After Tax and Minority Interest | 150 | 213 | 155 | 3% | -27% |
| Normalised Profit after Tax | 150 | 223 | 226 | 51% | 1% |
| Earnings Per Share - Face Value Re. 1 (Rs.) | 9.63 | 13.64 | 9.94 | | |
| Normalised Earnings Per Share | 9.63 | 14.33 | 14.53 | | |
| | (%i | | | (b | ps) |
| EBITDA Margins from Operations | 19.7% | 20.8% | 21.3% | 161 | 52 |
| Pharmaceuticals | 26.9% | 22.2% | 24.1% | (278) | 189 |
| Life Science Ingredients | 15.6% | 22.3% | 19.3% | 378 | (299) |
| Drug Discovery Solutions | 10.9% | 7.0% | 22.0% | 1,112 | 1,504 |
| Net Margins | 9.4% | 10.3% | 6.9% | (252) | (340) |